John Stone
Rheumatology · Boston, MANPI 1053346924
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $579,712 of the $926,107 with a category attached, or 62.6%. Amgen accounts for 69.0% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $544,627 and has fallen 92.9% since, to $38,584 in 2025. Among rheumatology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $2940.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$639K
- F. Hoffmann-la Roche AG$59K
- Sanofi$56K
- Argenx US, Inc.$43K
- Sanofi-aventis U.S. LLC$43K
- Hoffmann-la Roche Limited$16K
- plus $70K from 17 others
Across 98 payments — averaging $63,215 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3.9M
- Amgen$1.1M
- Principia Biopharma Inc.$854K
- E.r. Squibb & Sons, L.L.C.$283K
- Novartis Pharma AG$32K
- Argenx US, Inc.$32K
- plus $30K from 4 others
What the payments were for
- Consulting fees$305,39333%
- Speaking & faculty fees$579,71263%
- Travel & lodging$36,0694%
- Food & beverage$4,7381%
- Education$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 108 | $639,375 |
| F. Hoffmann-la Roche AG | 39 | $59,083 |
| Sanofi | 24 | $56,182 |
| Argenx US, Inc. | 33 | $43,244 |
| Sanofi-aventis U.S. LLC | 42 | $42,814 |
| Hoffmann-la Roche Limited | 4 | $15,516 |
| GSK | 16 | $13,827 |
| Novartis Pharma AG | 6 | $9,087 |
| E.r. Squibb & Sons, L.L.C. | 4 | $8,948 |
| Sanofi US Services Inc. | 8 | $8,873 |
| Merck | 4 | $7,350 |
| AstraZeneca(2 entities) | 3 | $4,787 |
| Genentech USA, Inc. | 1 | $4,000 |
| AbbVie(2 entities) | 4 | $3,500 |
| Genentech, Inc. | 4 | $3,022 |
| Regeneron | 1 | $1,740 |
| Pfizer | 1 | $1,500 |
| Novartis | 6 | $1,097 |
| Sobi, Inc | 1 | $962 |
| GRT US Holding, Inc. | 1 | $563 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $420 |
| Insmed, Inc. | 3 | $189 |
| Tanabe Pharma Corporation | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$926,107 in reported general payments places this provider in the 95th percentile of 265 rheumatology providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 17 | $169,172 |
| Xeljanz XrTofacitinib Citrate | 17 | $95,487 |
| Prednisone | 22 | $201 |
| Carvedilol | 12 | $114 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Boston
- Marilyn PikeBoston$1.4M
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Tanya LaidlawBoston$244K
- Tuhina NeogiBoston$242K
- Michael WeinblattBoston$228K
- Michael BrennerBoston$115K
- Zachary WallaceBoston$106K
- Flavia CastelinoBoston$96K
- Joerg ErmannBoston$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.